What doth summer bring?

As the vacation season begins, it seems like everyone (markets included) would benefit from a little time off. The BioCentury 100 managed to post a 5.5 percent gain in the second quarter despite a landslide of bad news at the end, including a failed Phase III study by Liposome (LIPO), Phase III trials put on hold by Cambridge NeuroScience (CNSI) and Idec (IDPH), and an FDA panel vote against approving Ilex Oncology (ILXO) non-Hodgkin's lymphoma product in AIDS.

But the BioCentury 100 is still 2 points shy of its 1996 close of 985.54, and the

Read the full 948 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE